Vaxcyte, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| Vaxcyte, Inc. | ||
| Date: February 24, 2026 | By: | /s/ Grant E. Pickering |
|---|---|---|
| Grant E. Pickering | ||
| Chief Executive Officer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Grant E. Pickering and Andrew Guggenhime, and each of them, as his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Grant E. Pickering | Chief Executive Officer and Director | February 24, 2026 |
| Grant E. Pickering | (Principal Executive Officer) | |
| /s/ Andrew Guggenhime | President and Chief Financial Officer | February 24, 2026 |
| Andrew Guggenhime | (Principal Financial Officer) | |
| /s/ Elvia Cowan | Senior Vice President, Finance and Chief Accounting Officer | February 24, 2026 |
| Elvia Cowan | (Principal Accounting Officer) | |
| /s/ Carlos Paya | Director | February 24, 2026 |
| Carlos Paya, M.D., Ph.D. | ||
| /s/ Olivier Brandicourt | Director | February 24, 2026 |
| Olivier Brandicourt, M.D. | ||
| /s/ Annie Drapeau | Director | February 24, 2026 |
| Annie Drapeau | ||
| /s/ John Furey | Director | February 24, 2026 |
| John Furey | ||
| /s/ Halley Gilbert | Director | February 24, 2026 |
| Halley Gilbert | ||
| /s/ Jacks Lee | Director | February 24, 2026 |
| Jacks Lee | ||
| /s/ Teri Loxam | Director | February 24, 2026 |
| Teri Loxam | ||
| /s/ Heath Lukatch | Director | February 24, 2026 |
| Heath Lukatch, Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.